Crizotinib in the treatment of generalized non‑small‑cell lung cancer – a case report

03/2017

MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

Targeted therapy on the basis of predictive biomarkers that predict the efficacy, at least some patients allows to individualize the treatment and in recent years led to improved treatment outcomes in patients with unfavorable diagnosis of NSCLC (non-small-cell lung cancer). One of these predictive biomarkers is a gene rearrangement EML-4-ALK and ROS1, where is indicated treatment with ALK and ROS1 inhibitors.

KEYWORDS

non-small-cell lung cancer, predictive biomarkers, gene rearrangement ALK, crizotinib